Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 1, 2011, Pages 51-59

  Johnson, Thomas V ^a,b   Gupta, Preeya K ^c   Vudathala, Daljit K ^d,e   Blair, Ian A ^d   Tanna, Angelo P ^f  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NATIONAL EYE INSTITUTE   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ARTICLE; DRUG DEGRADATION; DRUG MANUFACTURE; DRUG MONITORING; DRUG STABILITY; DRUG STORAGE; DRUG USE; HUMAN; LIQUID CHROMATOGRAPHY; SHELF LIFE; TANDEM MASS SPECTROMETRY; TEMPERATURE STRESS; THERMOSTABILITY; ULTRAVIOLET RADIATION;

AMIDES; ANTIHYPERTENSIVE AGENTS; CHROMATOGRAPHY, LIQUID; CLOPROSTENOL; DRUG STABILITY; HOT TEMPERATURE; HUMANS; OSMOLAR CONCENTRATION; PROSTAGLANDINS F, SYNTHETIC; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 79951985176     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0115     Document Type: Article

References (36)

1. Quigley, H.A., and Broman, A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90:262-267, 2006.
2. Resnikoff, S., Pascolini, D., Etya'ale, D., et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82:844-851, 2004.
3. Maier, P.C., Funk, J., Schwarzer, G., Antes, G., and Falck-Ytter, Y.T. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 331:134, 2005.
4. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713; discussion 829-830, 2002.
5. Heijl, A., Leske, M.C., Bengtsson, B., Hyman, L., Bengtsson, B., and Hussein, M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120:1268-1279, 2002.
6. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am. J. Ophthalmol. 130:429-440, 2000.
7. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126:498-505, 1998.
8. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126:487-497, 1998.
9. Bean, G.W., and Camras, C.B. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv. Ophthalmol. 53 Suppl 1:S69-S84, 2008.
10. Holmstrom, S., Buchholz, P., Walt, J., Wickstrom, J., and Aagren, M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr. Med. Res. Opin. 21:1875-1883, 2005.
11. Marquis, R.E., and Whitson, J.T. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 22:1-21, 2005. (Pubitemid 40188902)
12. Schwartz, K., and Budenz, D. Current management of glaucoma. Curr. Opin. Ophthalmol. 15:119-126, 2004.
13. Hylton, C., and Robin, A.L. Update on prostaglandin analogs. Curr. Opin. Ophthalmol. 14:65-69, 2003.
14. Johnson, T.V., Fan, S., Zhan, G., Camras, C.B., and Toris, C.B. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment. J. Glaucoma 19:356-364, 2010.
15. Lim, K.S., Nau, C.B., O'Byrne, M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology 115:790-795.e4, 2008.
16. Toris, C.B., Gabelt, B.T., and Kaufman, P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol. 53 Suppl 1:S107-S120, 2008.
17. Toris, C.B., Zhan, G., Fan, S., et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J. Glaucoma 16:189-195, 2007. (Pubitemid 46673350)
18. Christiansen, G.A., Nau, C.B., McLaren, J.W., and Johnson, D.H. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology 111:1658-1662, 2004. (Pubitemid 39179679)
19. Toris, C.B., Camras, C.B., and Yablonski, M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology 100:1297-1304, 1993. (Pubitemid 23274021)
20. Ziai, N., Dolan, J.W., Kacere, R.D., and Brubaker, R.F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111:1351-1358, 1993.
21. Novack, G.D., and Evans, R. Commercially available ocular hypotensive products: preservative concentration, stability, storage, and in-life utilization. J. Glaucoma 10:483-486, 2001. (Pubitemid 34001104)
22. Xalatan [Package Insert]. Pharmacia & Upjohn Company, Division of Pfizer Inc.; New York, NY: January 2009. www.pfizer.com/files/products/uspi- xalatan.pdf. Accessed July 27, 2010.
23. Lumigan [Package Insert]. Allergan Inc.; Irvine, CA: September 2006. www.allergan.com/assets/pdf/lumigan-pi.pdf. Accessed July 27, 2010.
24. Travatan [Package Insert]. Alcon Laboratories, Inc.; Fort Worth, TX: 2004. http://ecatalog.alcon.com/pi/travatan-us-en.pdf. Accessed July 27, 2010.
25. Hahn, S.R. Patient-centered communication to assess and enhance patient adherence to glaucoma medication. Ophthalmology 116:S37-S42, 2009.
26. Tsai, J.C. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology 116:S30-S36, 2009.
27. Budenz, D.L. A clinician's guide to the assessment and management of nonadherence in glaucoma. Ophthalmology 116:S43-S47, 2009.
28. Varma, R., Winarko, J., Kiat-Winarko, T., and Winarko, B. Concentration of latanoprost ophthalmic solution after 4 to 6 weeks' use in an eye clinic setting. Invest. Ophthalmol. Vis. Sci. 47:222-225, 2006.
29. Morgan, P.V., Proniuk, S., Blanchard, J., and Noecker, R.J. Effect of temperature and light on the stability of latanoprost and its clinical relevance. J. Glaucoma 10:401-405, 2001. (Pubitemid 33062656)
30. Reis, R., dos Santos, L.C., Vila, M.P., and Magacho, L. Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study. Clin. Ther. 26:2121-2127, 2004.
31. Mochizuki, H., Itakura, H., Takamatsu, M., and Kiuchi, Y. Efficacy of latanoprost when stored at room temperature. Hiroshima J. Med. Sci. 57:69-72, 2008.
32. Paolera, M.D., Kasahara, N., Umbelino, C.C., and Walt, J.G. Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: a patient-use study. BMC Ophthalmol. 8:11, 2008.
33. Fristrom, B., and Nilsson, S.E. A double masked comparison of the intraocular pressure reducing effect of latanoprost 0.005% and 0.001% administered once daily in open angle glaucoma and ocular hypertension. Br. J. Ophthalmol. 81:867-870, 1997.
34. Diestelhorst, M., Roters, S., and Krieglstein, G.K. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, doublemasked comparison with timolol 0.5%. Graefes Arch. Clin. Exp. Ophthalmol. 235:20-26, 1997.
35. Friedman, D.S., Okeke, C.O., Jampel, H.D., et al. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma. Ophthalmology 116:1097-1105, 2009.
36. Okeke, C.O., Quigley, H.A., Jampel, H.D., et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology 116:2286-2293, 2009.